BRISBANE, Calif., June 9, 2021 /PRNewswire/ — Second Genome, a tech-enabled biotechnology firm that extracts microbial genetic insights to make transformational precision therapies and biomarkers, at this time introduced that the Company will current a demo of Odessa, its proprietary massive information analytics software program that’s foundational to the Company’s multi-disciplinary microbiome discovery and growth platform, on the digital Microbiome Data Congress on June 9–10, 2021.
Odessa, half the Company’s sg-4sight platform, manages Next Generation Sequencing (NGS) datasets extra quickly and effectively in comparison with publicly accessible instruments, thus enabling the Company to course of massive quantities of information, conduct analytics and speed up the identification of proprietary biomarkers in a number of therapeutic areas, comparable to immuno-oncology, and discovery packages.
“With Odessa’s fast speed, built-in quality controls and scale of data processing, coupled with a full suite of analytics and machine learning tools, Second Genome has built the world’s largest curated and harmonized microbial genomics database which has multiple discovery applications for Second Genome and its collaborators,” stated Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome. “Analysis of diverse, expansive and real-world patient data sets is essential to maximize the potential of microbial insights to better understand the diversity of the microbiome and mine for predictors of therapy response and novel therapeutics. Odessa allows us to not only keep pace with the rapid growth of available microbiome sequence data but also contextualize the data to optimize biomarker targeting and other discovery initiatives.”
Sourcing from accessible public or proprietary NGS datasets, Odessa saves sequencing information — sometimes FASTQ/FASTA — into the cloud and maintains its location and metadata in a Relational Database Server (RDS) to handle massive quantities of sequencing information. While RDS administration is often carried out semi-manually, Odessa permits the Company to completely automate the downloading, high quality checking and processing of datasets from a number of sources, together with the National Center for Biotechnology Information Sequence Read Archive (NCBI-SRA), and might achieve this in a matter of a number of hours in comparison with a number of days for publicly accessible ingestion software program. Odessa’s built-in exploratory information evaluation instruments, together with metagenomic and differentially expressed gene evaluation, additionally allow extra environment friendly information visualization and evaluation.
The Odessa software program demo can be made accessible to all Microbiome Data Congress attendees, and extra details about Second Genome’s revolutionary drug and biomarker discovery platform might be discovered on the Company’s web site at https://www.secondgenome.com/development-platform.
About Second Genome
Second Genome is a tech-enabled biotechnology firm that extracts microbial genetic insights to make transformational precision therapies and biomarkers by means of medical growth and commercialization. We constructed a proprietary microbiome-based drug discovery and growth platform with machine-learning analytics, custom-made protein engineering methods, phage library screening, mass spec evaluation and CRISPR, that we couple with conventional drug growth approaches to progress the event of therapies and diagnostics for wide-ranging ailments. Second Genome is advancing its drug discovery and biomarker pipelines of precision therapeutics and biomarker packages in inflammatory bowel illness (IBD) and most cancers, with the lead program SG-2-0776 in IBD anticipated to enter medical growth in 2022. We additionally collaborate with business, educational and governmental companions to leverage our microbiome platform and information science. We maintain a strategic collaboration with Gilead Sciences, Inc., using our proprietary platform and complete information units to determine novel biomarkers related to medical response to Gilead’s investigational medicines. For extra data, please go to www.secondgenome.com.
SOURCE Second Genome